Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Ter Arkh ; 86(9): 65-70, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-25518508

RESUMEN

AIM: To evaluate the efficacy of cytoflavin in the treatment of patients with hypertensive encephalopathy (HE). SUBJECTS AND METHODS: One hundred and forty patients aged 39 to 73 years, diagnosed with HE, were examined and randomized to 2 groups. A study group (n = 74) received cytoflavin in a dose of 2 tablets b.i.d. on days 1 to 25 days inclusive during standard basic therapy. A comparison group (n = 66 persons) had standard basic therapy only. A control group consisted of 30 apparently healthy individuals. The investigators studied the frequency of headache, dizziness, and other complaints and the intensity of cephalalgic syndrome, by using a visual analog scale, the quality of life by the Medical Outcomes Study 36-Item Short-Form Health Survey (MOS SF-36) questionnaire, that of sleep by the subjective sleep characteristics questionnaire elaborated at the Moscow City Somnological Center, the level of asthenia by a subjective asthenia rating scale (Multidimensional Fatigue Inventory (MFI-20), and autonomic status, by applying objective and subjective scales on days 1 and 25 of therapy. RESULTS: The study has shown that cytoflavin used in the above dose for 25 days reduces the frequency and magnitude of complaints of headache, dizziness, "venous" complaints, the degree of autonomic and asthenic disorders, and impairments in the quality of sleep and life in the patients with HE at all disease stages. A stepwise discriminant analysis has indicated that the degree of cephalgic syndrome, and autonomic disorders, and worse sleep quality are the most effective points for using the energy-modifier cytoflavin. CONCLUSION: HE treatment based on the current pathogenetic principles may have a preventive impact on the development of HE or slow down the rate of its progression.


Asunto(s)
Mononucleótido de Flavina/administración & dosificación , Cefalea , Encefalopatía Hipertensiva , Inosina Difosfato/administración & dosificación , Astenia Neurocirculatoria , Niacinamida/administración & dosificación , Trastornos del Sueño-Vigilia , Succinatos/administración & dosificación , Administración Oral , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Monitoreo de Drogas , Metabolismo Energético/efectos de los fármacos , Femenino , Cefalea/diagnóstico , Cefalea/tratamiento farmacológico , Cefalea/etiología , Humanos , Encefalopatía Hipertensiva/complicaciones , Encefalopatía Hipertensiva/tratamiento farmacológico , Encefalopatía Hipertensiva/metabolismo , Encefalopatía Hipertensiva/fisiopatología , Encefalopatía Hipertensiva/psicología , Masculino , Persona de Mediana Edad , Astenia Neurocirculatoria/diagnóstico , Astenia Neurocirculatoria/tratamiento farmacológico , Astenia Neurocirculatoria/etiología , Dimensión del Dolor/métodos , Polisomnografía , Calidad de Vida , Índice de Severidad de la Enfermedad , Trastornos del Sueño-Vigilia/diagnóstico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Trastornos del Sueño-Vigilia/etiología , Resultado del Tratamiento , Escala Visual Analógica , Complejo Vitamínico B/administración & dosificación
2.
Artículo en Ruso | MEDLINE | ID: mdl-25042496

RESUMEN

OBJECTIVES: To study correlations between symptoms of hypertensive encephalopathy (HE), structural MRI changes of the brain and affective disorders in the perimenopausal period. MATERIALS AND METHODS: A study included 150 women who have been through natural menopause (group 1) and 100 women in the premenopausal (group 2). Somatic and neurological examination, MRI and psychometric scales for anxiety and depression were used. RESULTS AND CONCLUSIONS: Women with hypertensive encephalopathy in the postmenopausal period had signs of persistent psycho-emotional disorders (higher anxiety, depression of different severity) combined with structural changes in the brain, with their severity increasing with the progression of HE.


Asunto(s)
Encefalopatía Hipertensiva/diagnóstico , Posmenopausia , Ansiedad/complicaciones , Ansiedad/diagnóstico , Depresión/complicaciones , Depresión/diagnóstico , Femenino , Humanos , Encefalopatía Hipertensiva/complicaciones , Encefalopatía Hipertensiva/psicología , Persona de Mediana Edad
4.
Ter Arkh ; 82(12): 10-5, 2010.
Artículo en Ruso | MEDLINE | ID: mdl-21516731

RESUMEN

AIM: To study the clinical and instrumental characteristics of hypertensive encephalopathy (HE) in early stages, as well as the time course of their changes during long-term antihypertensive therapy (AHT). SUBJECTS AND METHODS: Prior to and after 9-month AHT, 57 patients aged 50-70 years who had uncomplicated grades 1-2 arterial hypertension (AH) with grades I-II HE underwent comprehensive examination comprising the studies of cognitive functions, quality of life (QL), hemorheology, and hemostasis, duplex scanning of great and intracerebral vessels, echocardiography, 24-hour blood pressure monitoring, magnetic resonance imaging. RESULTS: Early-stage HE was characterized by more cerebral complaints, higher rates of hypertensive crises, a greater degree of psychoautonomic syndrome, and worse QL. Focal brain lesions were detected in 74%; left ventricular hypertrophy (LVH) was diagnosed in 61% of cases. All the patients were observed to have cognitive dysfunctions. AHT (amlodipine, lisinopril) produced a good antihypertensive effect and substantial improvements of the patients' cognitive functions, health status, and QL. LVH regression was achieved. CONCLUSION: HE is a clinical manifestation of damage to the brain as the principal target organ in AH and should be therefore kept in mind in estimating the cardiovascular risk. The diagnosis of HE requires the use of tests to evaluate cognitive functions.


Asunto(s)
Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Encefalopatía Hipertensiva/psicología , Calidad de Vida , Anciano , Electrocardiografía Ambulatoria , Femenino , Estudios de Seguimiento , Humanos , Encefalopatía Hipertensiva/diagnóstico , Encefalopatía Hipertensiva/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Ultrasonografía Doppler Transcraneal
5.
Psychiatr Prax ; 33(4): 191-3, 2006 May.
Artículo en Alemán | MEDLINE | ID: mdl-16729404

RESUMEN

BACKGROUND: Carrying out dialysis against a patient's will poses specific legal and ethical problems. Decisions have to be made under time pressure, there is often an immediate threat to life, the intervention is rather difficult to carry out against a patient's will, and the same dilemma repeats itself continuously within some days. METHOD: We report on a 45-year-old man with moderate dementia due to hypertensive encephalopathy who was involuntarily admitted to a psychiatric hospital by a court order because of his refusal of dialysis. RESULTS: Dialysis could be carried out with moderate coercion in a general hospital and was subsequently accepted by the patient after two treatments. The protest of the psychiatric hospital against the obligation to provide dialysis by coercion was accepted by the superior court some weeks after discharge of the patient, because dialysis is not provided in the psychiatric hospital. DISCUSSION: Though a good outcome could be achieved in this particular case, many questions remain unclear concerning the feasibility of dialysis under coercion in cases of patients with impaired capacity to give informed consent, and the legal responsibility for the realization of court orders.


Asunto(s)
Coerción , Internamiento Obligatorio del Enfermo Mental/legislación & jurisprudencia , Demencia/psicología , Encefalopatía Hipertensiva/psicología , Competencia Mental/legislación & jurisprudencia , Diálisis Renal/psicología , Negativa del Paciente al Tratamiento/legislación & jurisprudencia , Alemania , Hospitales Generales/legislación & jurisprudencia , Hospitales Psiquiátricos/legislación & jurisprudencia , Humanos , Masculino , Persona de Mediana Edad , Derivación y Consulta/legislación & jurisprudencia
6.
J Affect Disord ; 85(3): 327-32, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15780703

RESUMEN

BACKGROUND: While patients with depression have been shown to have a greater incidence of vascular risk factors and structural brain changes, any association with dietary co-factors is unclear. METHODS: Forty-seven patients with major depression (mean age = 52.8 years, SD = 12.6) and 21 healthy volunteers (mean age = 54.7 years, SD = 9.1) underwent high-resolution magnetic resonance imaging scanning. T2-weighted films were scored for deep white matter (DWM), periventricular (PV), and subcortical (SC) hyperintensities. RESULTS: There was no difference in lesion severity between patients and control subjects. After controlling for age, vitamin B12 levels were predictive of DWM lesions in patients. DWM and SC lesions were associated with histories of hypertension and diabetes. LIMITATIONS: A relatively small sample of patients were recruited from specialist services and the findings may not represent those observed in larger or community-based cohorts. CONCLUSIONS: In patients with major depression, vitamin B12 levels and histories of hypertension and/or diabetes are predictive of white matter lesions.


Asunto(s)
Encéfalo/patología , Trastorno Depresivo Mayor/epidemiología , Diabetes Mellitus Tipo 2/epidemiología , Hipertensión/epidemiología , Arteriosclerosis Intracraneal/epidemiología , Imagen por Resonancia Magnética , Deficiencia de Vitamina B 12/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Corteza Cerebral/patología , Ventrículos Cerebrales/patología , Estudios de Cohortes , Comorbilidad , Trastorno Depresivo Mayor/diagnóstico , Trastorno Depresivo Mayor/patología , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/psicología , Femenino , Homocisteína/sangre , Humanos , Hipertensión/diagnóstico , Hipertensión/psicología , Encefalopatía Hipertensiva/diagnóstico , Encefalopatía Hipertensiva/epidemiología , Encefalopatía Hipertensiva/psicología , Arteriosclerosis Intracraneal/diagnóstico , Arteriosclerosis Intracraneal/psicología , Masculino , Persona de Mediana Edad , Valores de Referencia , Factores de Riesgo , Estadística como Asunto , Deficiencia de Vitamina B 12/diagnóstico , Deficiencia de Vitamina B 12/psicología
7.
Psychol Med ; 30(5): 1017-23, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12027039

RESUMEN

BACKGROUND: Previous longitudinal studies of the association between depression and cognitive dysfunction have had relatively short follow-up periods. This report presents a long-term study of the association between baseline syndromal depression and cognitive outcome measured 9 to 12 years later. METHODS: Self-CARE (D) depression, cognitive function and pre-morbid intelligence were recorded on 1083 subjects on entry to the Medical Research Council trial of treatment of hypertension in older adults in 1983-5. In 1994-5, we aimed to re-interview all survivors to assess cognitive function using the MMSE. We used multivariate analysis to explore whether baseline depression predicted cognitive outcome after this long follow-up period. RESULTS: Baseline depression was crudely associated with poorer cognitive outcome at time 2. However, this long-term prospective association was no longer apparent after adjusting for baseline cognitive performance, which was associated with baseline depression and robustly predicted cognitive outcome at time 2. We found that gender modified the association between depression and poorer cognitive outcome, so that the association was statistically significant only among men. CONCLUSION: Propensity for depression and failing cognition may have common determinants that still need to be established by future neurobiological investigations in conjunction with further long-term prospective epidemiological research.


Asunto(s)
Trastornos del Conocimiento/diagnóstico , Trastorno Depresivo/diagnóstico , Escala del Estado Mental/estadística & datos numéricos , Anciano , Trastornos del Conocimiento/psicología , Trastorno Depresivo/psicología , Femenino , Estudios de Seguimiento , Humanos , Encefalopatía Hipertensiva/diagnóstico , Encefalopatía Hipertensiva/psicología , Inteligencia , Masculino , Inventario de Personalidad/estadística & datos numéricos , Valor Predictivo de las Pruebas , Estudios Prospectivos , Psicometría , Factores de Riesgo
8.
Neurology ; 53(9): 1948-52, 1999 Dec 10.
Artículo en Inglés | MEDLINE | ID: mdl-10599763

RESUMEN

OBJECTIVE: To examine whether baseline high blood pressure and antihypertensive treatment predicts cognitive decline in elderly individuals. METHODS: A longitudinal population-based study of elderly individuals (n = 1,373) in Nantes (western France) was undertaken. Individuals 59 to 71 years of age were selected from electoral rolls. High blood pressure at baseline was defined as systolic blood pressure > or =160 mm Hg or diastolic blood pressure > or =95 mm Hg. Cognitive decline was defined as a drop of 4 points or more on the Mini-Mental State Examination between baseline and the 4-year assessment. RESULTS: There is an association between high blood pressure at baseline and cognitive decline at the 4-year assessment (odds ratio, 2.8; 95% CI, 1.6 to 5.0). In participants with high blood pressure, the risk of cognitive decline was 4.3 (95% CI, 2.1 to 8.8) in those without antihypertensive therapy and 1.9 (95% CI, 0.8 to 4.4) in those being treated. In participants with high blood pressure both at baseline and at the 2-year assessment, the risk for untreated participants was 6.0 (95% CI, 2.4 to 15.0) compared with 1.3 (95% CI, 0.3 to 4.9) in treated participants. CONCLUSIONS: High blood pressure was associated with cognitive decline. In individuals with high blood pressure, cognitive decline occurred in a relatively short time period and the risk was highest in untreated hypertensive patients.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Trastornos del Conocimiento/diagnóstico , Encefalopatía Hipertensiva/diagnóstico , Anciano , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/psicología , Antihipertensivos/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos del Conocimiento/psicología , Femenino , Estudios de Seguimiento , Humanos , Encefalopatía Hipertensiva/tratamiento farmacológico , Encefalopatía Hipertensiva/psicología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Oportunidad Relativa , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...